HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer
M.A. Bergamino, Elena López‐Knowles, Gabriele Morani, Holly Tovey et autres
gb (code pays fourni par la source)